Anakinra
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Anakinra: From IL-1-Driven Inflammatory Disease to Familial Mediterranean Fever
One-Sentence Summary
Anakinra is a recombinant IL-1 receptor antagonist; the evidence pack does not contain a documented original indication (Anakinra holds 0 marketing authorizations in Norway), but its IL-1-blocking mechanism is consistently referenced across the literature reviewed here. TxGNN screened 10 candidate indications for this drug, and among them Familial Mediterranean Fever (FMF) shows by far the strongest real-world support — anakinra is already used clinically as second-line therapy for colchicine-resistant/intolerant FMF, backed by 18 publications (though 0 registered clinical trials) in this dataset.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file — Anakinra has no marketing authorization in Norway (0 licenses); indication text unavailable from regulatory dataset |
| Predicted New Indication | Familial Mediterranean Fever (autosomal recessive) |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L3 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, no structured mechanism-of-action record is available for anakinra in this evidence pack (original_moa is a documented data gap, DG002). However, the mechanistic rationale text embedded across multiple predicted indications in this same evidence pack consistently and independently identifies anakinra as a recombinant IL-1 receptor antagonist that blocks IL-1α/β signaling — this is corroborating information drawn directly from the evidence, not an external assumption.
FMF is caused by MEFV gene mutations that produce a dysfunctional pyrin protein, leading to unregulated inflammasome activation and excessive IL-1β release. This creates a direct mechanistic match with anakinra's IL-1 blockade: the drug is not merely "theoretically" applicable — the literature reviewed here shows it is already used in real-world clinical practice as rescue/second-line therapy for FMF patients who fail or cannot tolerate colchicine (the first-line standard of care), including cases complicated by AA amyloidosis and renal failure.
Because Norway has no marketing authorization for anakinra on file, this "new indication" is best understood as a known, internationally-supported off-label/guideline use that is not yet reflected in local regulatory status — the gap here is regulatory/administrative rather than mechanistic or clinical.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21277619 | 2011 | Case Series/Review | Semin Arthritis Rheum | IL-1 receptor antagonism (anakinra) and anti-IL-1 mAbs proposed as rational treatment given pyrin's role in IL-1 maturation/secretion |
| 23322405 | 2013 | Review/Cohort | Clin Rev Allergy Immunol | Comprehensive review of IL-1β biological treatment (anakinra/canakinumab) in colchicine-refractory FMF |
| 19033248 | 2009 | Case Report | Nephrol Dial Transplant | Successful anakinra treatment of FMF before/after renal transplantation, with preserved graft outcome |
| 21931121 | 2012 | Case Series | Nephrol Dial Transplant | Dramatic clinical improvement with IL-1 inhibitor treatment in FMF complicated by amyloidosis and renal failure |
| 23928237 | 2013 | Case Report | Joint Bone Spine | FMF-associated myositis and spondyloarthritis successfully controlled with anakinra |
| 34550430 | 2022 | Case Series | Rheumatol Int | Canakinumab effective in FMF patients resistant/intolerant to colchicine and/or anakinra (real-world experience) |
| 28585601 | 2017 | Case Series | JPMA | Anakinra used successfully in four children with colchicine-resistant FMF, including sibling cases |
| 31205631 | 2019 | Review | Mediterr J Hematol Infect Dis | Overview of FMF clinical impact and treatment algorithms, incorporating IL-1 blockade for colchicine-resistant cases |
| 26572612 | 2016 | Review | Curr Med Chem | Review of colchicine, biologic agents (including anakinra), and emerging therapies for FMF |
| 23867542 | 2014 | Review | Clin Pharmacol Ther | Progression from colchicine to biologic (IL-1 antagonist) therapies in FMF management |
Safety Considerations
Please refer to the package insert for safety information.
(Note: the underlying evidence pack flags TFDA/label warnings and contraindications as a Blocking-severity data gap (DG001) — this must be resolved before any formal safety review can proceed; see Conclusion below.)
Other Candidate Indications Identified by TxGNN (Same Drug)
Anakinra's evidence pack contains 10 TxGNN-ranked candidates in total. For transparency, the two other candidates with real (non-L5) evidence support are listed here alongside the top-scoring but unsupported prediction:
| Rank | Disease | TxGNN Score | Evidence Level | Recommendation | Note |
|---|---|---|---|---|---|
| 1 | Extracutaneous mastocytoma | 99.93% | L5 | Hold | Highest raw TxGNN score, but zero clinical/literature evidence; KIT-driven pathology has no clear mechanistic link to IL-1 blockade |
| 3 | Familial Mediterranean Fever | 99.89% | L3 | Proceed with Guardrails | Primary candidate in this report — strong mechanistic and real-world clinical support |
| 9 | Pyogenic autoinflammatory syndrome (PAPA/PSTPIP1 spectrum) | 99.83% | L3 | Proceed with Guardrails | Second strongest candidate; PSTPIP1-driven IL-1β overproduction, direct anakinra treatment reports exist |
| 4 | Aggressive systemic mastocytosis | 99.88% | L4 | Hold | Literature retrieved actually describes Schnitzler syndrome, not mastocytosis — likely label mismatch, needs manual verification |
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Familial Mediterranean Fever has the strongest evidence base among all TxGNN-predicted indications for anakinra — pyrin/IL-1 inflammasome pathophysiology directly matches the drug's mechanism, and multiple case series/reviews confirm real-world use in colchicine-resistant patients. However, evidence is limited to L3 (no RCTs), and anakinra currently holds zero marketing authorizations in Norway, so this cannot proceed as an unconditional "Go."
To proceed, the following is needed:
- Resolve the Blocking safety data gap (DG001): obtain TFDA/official label warnings, contraindications, and DDI data before any S1 safety review
- Obtain structured MOA documentation from DrugBank (DG002) to formally confirm IL-1 receptor antagonist classification
- Clarify Norway/EU regulatory pathway status for anakinra, including any existing off-label use precedent for FMF
- Given the absence of RCTs, consider prospective or registry-based studies to strengthen the evidence level beyond L3
- Manually verify TxGNN disease-label accuracy for lower-confidence candidates (e.g., rank 4's literature mismatch with Schnitzler syndrome) before further screening resources are allocated
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.